All In Biotech

NDA 018962 · Hospira

Manganese Chloride In Plastic Container

Manganese Chloride · Injection

Priority review

Last checked: Nov 20, 2026Latest source record: Dec 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Jun 26, 1986

Approved uses

1

Original approval plus efficacy supplements

Registered trials

15

3 Phase 3, 2 recruiting

FAERS reports

276

183 serious, 12 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 15, 2026.

INDICATIONS AND USAGE Manganese 0.1 mg/mL (Manganese Chloride Injection, USP) is indicated for use in adult patients as a supplement to intravenous solutions given for TPN. Administration helps to maintain manganese serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 26, 1986 Original approval · priority review
1 products under this application
  • MANGANESE CHLORIDE IN PLASTIC CONTAINER · MANGANESE CHLORIDE EQ 0.1MG MANGANESE/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Manganese Chloride" as an intervention, any sponsor and status, largest first.

All 15 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue36
  • headache28
  • nausea25
  • feeling abnormal21
  • dizziness20
  • pain20
  • anxiety18
  • diarrhoea18
  • asthenia17
  • drug ineffective17
  • weight decreased17
  • dyspnoea16

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20054
20063
20073
20083
20097
20107
20116
20128
20137
201411
201515
201629
201717
201831
201931
202019
202116
202220
202312
20249
20258
20267

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 10 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.